{"title":"色素基底管囊性基底细胞癌:深色皮肤的诊断挑战。","authors":"Biswanath Behera, Rashmi Kumari, Devinder Mohan Thappa, Debasis Gochhait, Pavithra Ayyanar","doi":"10.1111/ajd.13540","DOIUrl":null,"url":null,"abstract":"1. Curry JL, Tetzlaff MT, Nagarajan P et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J. Cutan. Pathol. 2017; 44: 158–76. 2. Wang LL, Patel G, Chiesa-Fuxench ZC et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018; 154: 1057–61. 3. Zitouni NB, Arnault J-P, Dadban A et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res. 2019; 29: 212–5. 4. Liu RC, Sebaratnam DF, Jackett L et al. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J. Dermatol. 2018; 59: e152–4. 5. Blakeway EA, Elshimy N, Muinonen-Martin A et al. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Melanoma Res. 2019; 29: 338–41. doi: 10.1111/ajd.13540","PeriodicalId":243138,"journal":{"name":"The Australasian journal of dermatology","volume":" ","pages":"e349-e351"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/ajd.13540","citationCount":"1","resultStr":"{\"title\":\"Pigmented infundibulocystic basal cell carcinoma: A diagnostic challenge in dark skin.\",\"authors\":\"Biswanath Behera, Rashmi Kumari, Devinder Mohan Thappa, Debasis Gochhait, Pavithra Ayyanar\",\"doi\":\"10.1111/ajd.13540\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"1. Curry JL, Tetzlaff MT, Nagarajan P et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J. Cutan. Pathol. 2017; 44: 158–76. 2. Wang LL, Patel G, Chiesa-Fuxench ZC et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018; 154: 1057–61. 3. Zitouni NB, Arnault J-P, Dadban A et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res. 2019; 29: 212–5. 4. Liu RC, Sebaratnam DF, Jackett L et al. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J. Dermatol. 2018; 59: e152–4. 5. Blakeway EA, Elshimy N, Muinonen-Martin A et al. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Melanoma Res. 2019; 29: 338–41. doi: 10.1111/ajd.13540\",\"PeriodicalId\":243138,\"journal\":{\"name\":\"The Australasian journal of dermatology\",\"volume\":\" \",\"pages\":\"e349-e351\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1111/ajd.13540\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Australasian journal of dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajd.13540\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Australasian journal of dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.13540","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Pigmented infundibulocystic basal cell carcinoma: A diagnostic challenge in dark skin.
1. Curry JL, Tetzlaff MT, Nagarajan P et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J. Cutan. Pathol. 2017; 44: 158–76. 2. Wang LL, Patel G, Chiesa-Fuxench ZC et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018; 154: 1057–61. 3. Zitouni NB, Arnault J-P, Dadban A et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res. 2019; 29: 212–5. 4. Liu RC, Sebaratnam DF, Jackett L et al. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J. Dermatol. 2018; 59: e152–4. 5. Blakeway EA, Elshimy N, Muinonen-Martin A et al. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Melanoma Res. 2019; 29: 338–41. doi: 10.1111/ajd.13540
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
